Skip to main content
NewslettersWatchlist

Spectral Medical Inc(EDT-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.4200
Day High0.4300
Open:0.4300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Spectral Medical Inc down on Monday (EDT)
AI-generated - The Globe and Mail
Spectral Medical: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (EDT)
GlobeNewswire
Spectral Medical Provides Tigris Trial Update
GlobeNewswire
Spectral Medical Chair to Retire From the Board of Directors
GlobeNewswire
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update
GlobeNewswire
Spectral Medical Provides February Tigris Trial Update
GlobeNewswire
Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation
GlobeNewswire
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
GlobeNewswire
Spectral Medical Provides Early February Tigris Trial Update
GlobeNewswire
Spectral Medical Provides January Tigris Trial Update
Baystreet
Stocks in play: Spectral Medical Inc.
GlobeNewswire
Spectral Medical Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial
GlobeNewswire
Spectral Medical Provides Tigris Trial Update
GlobeNewswire
Spectral Medical Provides November Tigris Trial Update
Baystreet
Stocks in play: Spectral Medical Inc.
GlobeNewswire
Spectral Medical Announces CFO Departure
GlobeNewswire
Spectral Medical Announces Publication of Tigris Trial Methods Paper and Simulation of Results
ACCESSWIRE
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
GlobeNewswire
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
GlobeNewswire
Spectral Medical Provides Tigris Trial Update
GlobeNewswire
Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic
GlobeNewswire
Spectral Medical Provides Tigris Trial Update
GlobeNewswire
Spectral Medical Provides Board Update
GlobeNewswire
Spectral Medical Supports World Sepsis Day
GlobeNewswire
Spectral Medical Featured in New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Septic Shock
GlobeNewswire
CORRECTION – Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing
Baystreet
Stocks in play: Spectral Medical Inc.
GlobeNewswire
Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing
AI-generated - The Globe and Mail
Spectral Medical: Top 10 Undervalued Healthcare Sector Stocks on TSX (EDT)
Baystreet
Stocks in play: Spectral Medical Inc.
GlobeNewswire
Spectral Medical Inc. Announces Upsizing of Previously Announced Bought Deal Convertible Note Financing to C$5.5M
GlobeNewswire
Spectral Medical Highlights New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Shock

Profile

Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The company has one reporting segment Spectral Medical Inc. The Dialco Medical Inc. operations were considered discontinued by the company.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.